Press release

Amgen's Rare Autoimmune Disease Candidate Shows Improvement In Disease Burden In Treating Sjögren's Syndrome

Amgen Inc (NASDAQ: AMGN) released new data from its Phase 2 study of dazodalibep for Sjögren's, a chronic (long-lasting) autoimmune disorder that happens when the immune system attacks the glands that make moisture in the eyes, mouth, and other parts of the body.

Also Read: Amgen Lifts Annual Outlook After Q3 Performance, But Stock Still Falls - Here's Why.

The first patient population included patients with moderate to severe systemic disease activity as ...

Full story available on

Disclaimer: The views, recommendations, and opinions expressed in this content belong solely to the third-party experts. This site was not involved in the writing and production of this article.

Disclaimer Press Release Banner